This week, the overall grades of 40 Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Regeneron Pharmaceuticals, Inc. (REGN) earns a F this week, moving down from last week’s grade of D. Regeneron Pharmaceuticals, Inc. researches, develops and commercializes therapeutics to treat human disorders and conditions. For more information, get Portfolio Grader’s complete analysis of REGN stock.

Agios Pharmaceuticals, Inc. (AGIO) gets weaker ratings this week as last week’s C drops to a D. The company also gets F’s in earnings surprise, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of AGIO stock.

Slipping from a C to a D rating, Spark Therapeutics, Inc. (ONCE) takes a hit this week. The company also gets F’s in earnings momentum and return on equity. For more information, get Portfolio Grader’s complete analysis of ONCE stock.

This is a rough week for SAGE Therapeutics, Inc. (SAGE). The company’s rating falls to D from the previous week’s C. The company also gets F’s in earnings surprise and return on equity. For more information, get Portfolio Grader’s complete analysis of SAGE stock.

Neurocrine Biosciences, Inc. (NBIX) slips from a C to a D this week. Neurocrine Biosciences, Inc. is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of NBIX stock.

This week, Alnylam Pharmaceuticals, Inc (ALNY) drops from a D to a F rating. Alnylam Pharmaceuticals, Inc engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ALNY stock.

Ophthotech Corp. (OPHT) is having a tough week. The company’s rating falls from a D to a F. The company also gets F’s in sales growth and free cash flow. For more information, get Portfolio Grader’s complete analysis of OPHT stock.

Alder Biopharmaceuticals, Inc. (ALDR) experiences a ratings drop this week, going from last week’s C to a D. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ALDR stock.

Juno Therapeutics, Inc. (JUNO) declines this week from a D to a F. The company also gets F’s in earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of JUNO stock.

Retrophin, Inc.’s (RTRX) rating weakens this week, dropping to a D versus last week’s C. The company also gets F’s in operating margin growth, earnings growth, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of RTRX stock.

This week, Bellicum Pharmaceuticals Inc’s (BLCM) rating worsens to a D from the company’s C rating a week ago. The company also gets F’s in earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of BLCM stock.

This week, Flexion Therapeutics, Inc. (FLXN) drops from a C to a D rating. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of FLXN stock.

This week, Forward Pharma A/S Sponsored ADR’s (FWP) rating worsens to a D from the company’s C rating a week ago. The company also gets F’s in earnings revisions and return on equity. For more information, get Portfolio Grader’s complete analysis of FWP stock.

Voyager Therapeutics, Inc. (VYGR) slips from a D to a F this week. The company also gets F’s in sales growth and return on equity. For more information, get Portfolio Grader’s complete analysis of VYGR stock.

This is a rough week for Esperion Therapeutics, Inc. (ESPR). The company’s rating falls to F from the previous week’s D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ESPR stock.

CytomX Therapeutics, Inc. (CTMX) gets weaker ratings this week as last week’s D drops to a F. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of CTMX stock.

Cidara Therapeutics, Inc. (CDTX) experiences a ratings drop this week, going from last week’s D to a F. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CDTX stock.

MiMedx Group, Inc.’s (MDXG) rating weakens this week, dropping to a D versus last week’s C. MiMedx Group, Inc. operates as a medical device company. The company also gets F’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of MDXG stock.

Recro Pharma, Inc. (REPH) is having a tough week. The company’s rating falls from a C to a D. The company also gets F’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of REPH stock.

Slipping from a D to a F rating, Immune Design Corp. (IMDZ) takes a hit this week. The company also gets F’s in earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of IMDZ stock.

Inovio Pharmaceuticals, Inc. (INO) declines this week from a C to a D. Inovio Pharmaceuticals, Inc. engages in the discovery and development of synthetic vaccines and immune therapies focusing on cancers and infectious diseases. The company also gets F’s in sales growth, earnings growth, earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of INO stock.

NantKwest, Inc. (NK) earns a F this week, moving down from last week’s grade of D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of NK stock.

This week, Ignyta, Inc.’s (RXDX) rating worsens to a F from the company’s D rating a week ago. The company also gets F’s in earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of RXDX stock.

This is a rough week for Synergy Pharmaceuticals, Inc. (SGYP). The company’s rating falls to D from the previous week’s C. Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of drugs to treat gastrointestinal disorders and diseases. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of SGYP stock.

Vital Therapies, Inc. (VTL) declines this week from a D to a F. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of VTL stock.

Cyclacel Pharmaceuticals, Inc. (CYCC) is having a tough week. The company’s rating falls from a C to a D. Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery, development and commercialization of mechanism-targeted drugs to treat human cancers and other serious disorders. The company also gets F’s in sales growth, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CYCC stock.

Adaptimmune Therapeutics PLC Sponsored ADR (ADAP) gets weaker ratings this week as last week’s D drops to a F. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of ADAP stock.

Slipping from a D to a F rating, Caladrius Biosciences, Inc. (CLBS) takes a hit this week. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CLBS stock.

Aeterna Zentaris Inc.’s (AEZS) rating weakens this week, dropping to a D versus last week’s C. Aeterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology with expertise in drug discovery, development and commercialization. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of AEZS stock.

aTyr Pharma, Inc. (LIFE) slips from a D to a F this week. ATyr Pharma, Inc. offers a broad range of products and services, including systems, instruments, reagents, and custom services. The company also gets F’s in earnings revisions, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of LIFE stock.

This week, Organovo Holdings, Inc. (ONVO) drops from a C to a D rating. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ONVO stock.

Onconova Therapeutics Inc. (ONTX) experiences a ratings drop this week, going from last week’s D to a F. The company also gets F’s in earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ONTX stock.

Lpath, Inc. (LPTN) earns a D this week, moving down from last week’s grade of C. Lpath, Inc. is a drug discovery company with a focus on bioactive signaling lipids as targets for treating and diagnosing human diseases. The company also gets F’s in sales growth, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of LPTN stock.

Rigel Pharmaceuticals, Inc. (RIGL) slips from a C to a D this week. Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of RIGL stock.

This is a rough week for PDL BioPharma, Inc. (PDLI). The company’s rating falls to F from the previous week’s D. PDL BioPharma, Inc. engages in intellectual property asset management and patent portfolio and related assets investment activities. The company also gets F’s in sales growth, earnings growth, earnings revisions, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of PDLI stock.

Nivalis Therapeutics, Inc.’s (NVLS) rating weakens this week, dropping to a F versus last week’s D. Nivalis Therapeutics, Inc. manufactures, sells, and supports equipment used in the fabrication of chips and semiconductors. The company also gets F’s in earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of NVLS stock.

This week, Idera Pharmaceuticals, Inc.’s (IDRA) rating worsens to a F from the company’s D rating a week ago. Idera Pharmaceuticals, Inc. is engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-Like Receptors (TLRs) to treat infectious diseases, autoimmune and inflammatory diseases, cancer, asthma and allergies, and for use as vaccine adjuvants. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of IDRA stock.

Pluristem Therapeutics Inc. (PSTI) declines this week from a C to a D. Pluristem Therapeutics Inc. develops Messenchymal stem cell production technology and commercializes cell therapy products. The company also gets F’s in sales growth, earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of PSTI stock.

RXi Pharmaceuticals Corporation (RXII) experiences a ratings drop this week, going from last week’s D to a F. The company also gets F’s in earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of RXII stock.

Slipping from a D to a F rating, Novavax, Inc. (NVAX) takes a hit this week. Novavax, Inc. creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle technology. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of NVAX stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.